ELTXHealthcare · BiotechnologyELTX Stock Forecast: Elicio Therapeutics, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Elicio Therapeutics, Inc. hold a median 12-month price target of $23 — +704.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ELTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Elicio Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (79): Sales and profits are climbing, and climbing faster than before.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Elicio Therapeutics, Inc. — and when they’d sell — is the membership.
ELTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ELTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +704.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 June 2026 | Ladenburg Thalmann | Assumes | Buy | $12 |
| 16 June 2026 | Jones Trading | Downgrade | Hold | — |
| 15 June 2026 | HC Wainwright & Co. | Maintains | Buy | $17 → $23 |
| 10 June 2026 | B. Riley Securities | Initiates | Buy | — |
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Apr 2026 | Ladenburg Thalmann | Initiates | Buy | — |
| 13 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Mar 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 17 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2024 | Jones Trading | Initiates | Buy | — |
| 23 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Apr 2024 | Oppenheimer | Reiterates | Perform | — |
| 17 Jan 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Oct 2023 | HC Wainwright & Co. | Assumes | Buy | $12 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ELTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Elicio Therapeutics, Inc. (ELTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 5.8×
- Price / sales
- —
- Price / book
- −35.6×
- EV / EBITDA
- −1.4×
Cheaper than 65% of US stocks
Cheaper than 99% of US stocks
Cheaper than 70% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −1076.3%
- Return on assets
- −92.4%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ELTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELTX appears on the weeks it earns a place.
Frequently asked questions about ELTX stock
What is the ELTX stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Elicio Therapeutics, Inc. have a median 12-month price target of $23, with estimates ranging from $10 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ELTX stock a buy right now?
Of the 4 analysts covering Elicio Therapeutics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elicio Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ELTX?
As at 1 Aug 2026, Elicio Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).
Will ELTX stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +704.2% from the last close, and Ticker Nerd's factor model ranks Elicio Therapeutics, Inc. 36 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ELTX stock forecast for 2030?
No analyst covering Elicio Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $27 over the next 12 months.
How has ELTX stock performed over the past year?
Elicio Therapeutics, Inc. returned -71.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Elicio Therapeutics, Inc. do?
Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer.
About Elicio Therapeutics, Inc.
Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company engineers next-generation vaccines, immunomodulators, and adjuvants built on its proprietary lymph node–targeting Amphiphile (AMP) platform, designed to enhance the education, activation, and amplification of cancer-specific T cells. Its lead program, ELI-002, is an off-the-shelf, lymph node–targeted therapeutic vaccine candidate directed at the most common KRAS mutations implicated across a broad range of solid tumors, including pancreatic and colorectal cancers. By concentrating immune stimulation in lymph nodes, Elicio Therapeutics aims to generate potent and durable anti-tumor immune responses in high-prevalence, hard-to-treat cancers. The company maintains a diversified oncology pipeline based on the AMP platform, including AMP-powered cancer vaccines and AMP-DNA adjuvant technologies under clinical and preclinical development. Elicio Therapeutics is headquartered in Boston, Massachusetts, and operates within the global biotechnology and oncology research ecosystem.
CEO Mr. Robert T. Connelly · 33 employees · United States · https://elicio.com